X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs NOVARTIS - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD NOVARTIS LUPIN LTD/
NOVARTIS
 
P/E (TTM) x 162.8 298.8 54.5% View Chart
P/BV x 3.0 25.5 11.9% View Chart
Dividend Yield % 0.8 1.4 57.8%  

Financials

 LUPIN LTD   NOVARTIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
NOVARTIS
Mar-17
LUPIN LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,750855 204.7%   
Low Rs1,384666 207.9%   
Sales per share (Unadj.) Rs387.4219.0 176.9%  
Earnings per share (Unadj.) Rs56.619.1 296.5%  
Cash flow per share (Unadj.) Rs76.820.3 378.5%  
Dividends per share (Unadj.) Rs7.5010.00 75.0%  
Dividend yield (eoy) %0.51.3 36.4%  
Book value per share (Unadj.) Rs298.9307.0 97.4%  
Shares outstanding (eoy) m451.5829.96 1,507.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.03.5 116.5%   
Avg P/E ratio x27.739.8 69.5%  
P/CF ratio (eoy) x20.437.5 54.4%  
Price / Book Value ratio x5.22.5 211.6%  
Dividend payout %13.252.4 25.3%   
Avg Mkt Cap Rs m707,51322,779 3,106.0%   
No. of employees `00016.80.7 2,491.4%   
Total wages/salary Rs m28,4951,393 2,045.6%   
Avg. sales/employee Rs Th10,418.39,736.2 107.0%   
Avg. wages/employee Rs Th1,697.02,066.8 82.1%   
Avg. net profit/employee Rs Th1,523.0849.0 179.4%   
INCOME DATA
Net Sales Rs m174,9436,562 2,665.9%  
Other income Rs m1,065702 151.8%   
Total revenues Rs m176,0087,264 2,423.1%   
Gross profit Rs m44,931259 17,354.7%  
Depreciation Rs m9,12236 25,410.3%   
Interest Rs m1,5257 21,184.7%   
Profit before tax Rs m35,349917 3,853.6%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,785345 2,835.4%   
Profit after tax Rs m25,575572 4,469.5%  
Gross profit margin %25.73.9 651.0%  
Effective tax rate %27.737.6 73.6%   
Net profit margin %14.68.7 167.7%  
BALANCE SHEET DATA
Current assets Rs m119,5429,731 1,228.4%   
Current liabilities Rs m61,2061,830 3,343.9%   
Net working cap to sales %33.3120.4 27.7%  
Current ratio x2.05.3 36.7%  
Inventory Days Days7649 156.1%  
Debtors Days Days9025 357.2%  
Net fixed assets Rs m131,66057 230,174.7%   
Share capital Rs m903141 641.9%   
"Free" reserves Rs m134,0739,056 1,480.5%   
Net worth Rs m134,9769,196 1,467.7%   
Long term debt Rs m56,4780-   
Total assets Rs m266,07311,499 2,313.8%  
Interest coverage x24.2128.4 18.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.70.6 115.2%   
Return on assets %10.25.0 202.1%  
Return on equity %18.96.2 304.5%  
Return on capital %19.310.1 191.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m81,885129 63,525.7%   
Fx outflow Rs m21,5061,734 1,240.3%   
Net fx Rs m60,378-1,605 -3,761.9%   
CASH FLOW
From Operations Rs m41,148-380 -10,842.6%  
From Investments Rs m-25,2874,208 -601.0%  
From Financial Activity Rs m4,332-3,318 -130.6%  
Net Cashflow Rs m20,193510 3,958.5%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 31.9 1.6 1,993.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.5 47.0%  
Shareholders   98,259 41,647 235.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS